Table 2

Study definitions of successful tolerance, partial response study failure, and relapse

Successful toleranceNegative inhibitor titer, FVIII recovery ≥ 66% of expected, and FVIII recovery ≥ 6 h
Partial response After 33 mo of ITI, negative inhibitor titer but persistently abnormal recovery or half-life; responding clinically to FVIII replacement without an anamnestic increase in inhibitor titer 
Study failure Failure of the inhibitor to decline by ≥ 20% over any 6-mo period after the first 3 mo of immune tolerance induction (ITI); or failure to achieve tolerance or partial response after 33 mo on ITI; or withdrawal from the study for any reason before tolerance was achieved 
Relapse Inhibitor recurrence during the 12-mo follow-up period on prophylaxis after tolerance was achieved, as evidenced by recurrent positive Bethesda titer or a decline in FVIII recovery or half-life below study limits 
Successful toleranceNegative inhibitor titer, FVIII recovery ≥ 66% of expected, and FVIII recovery ≥ 6 h
Partial response After 33 mo of ITI, negative inhibitor titer but persistently abnormal recovery or half-life; responding clinically to FVIII replacement without an anamnestic increase in inhibitor titer 
Study failure Failure of the inhibitor to decline by ≥ 20% over any 6-mo period after the first 3 mo of immune tolerance induction (ITI); or failure to achieve tolerance or partial response after 33 mo on ITI; or withdrawal from the study for any reason before tolerance was achieved 
Relapse Inhibitor recurrence during the 12-mo follow-up period on prophylaxis after tolerance was achieved, as evidenced by recurrent positive Bethesda titer or a decline in FVIII recovery or half-life below study limits 

From the consensus proceedings from the Second International Conference on Immune Tolerance Therapy, Bonn, Germany, 1997 (unpublished).

or Create an Account

Close Modal
Close Modal